X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia
Figure 1 Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib Monotherapy With or Without CXCR4…